Top 10 Questions Related to Factor VIIIΑ Mimetic Therapy for People with Hemophilia A

Target Audience

The educational design of this activity addresses the needs of hematology advanced practice providers (APPs), including nurse practitioners (NPs) and physician assistants (PAs), as well as hematology nurses involved in the treatment of patients with hematologic disorders, especially hemophilia A.

Program Overview

Hemophilia A is a rare, X-linked bleeding disorder caused by a deficiency of factor VIII (FVIII). Although prophylactic factor replacement has long been a standard of care, frequent intravenous dosing, the risk of inhibitor development, and substantial treatment burden continue to limit outcomes and quality of life for many people with hemophilia A. Nonfactor therapies have transformed prophylaxis, and FVIIIα mimetics—including emicizumab and next-generation agents such as denecimig (Mim8) and NXT007—offer subcutaneous administration and less frequent dosing, with important differences in mechanism of action, efficacy, safety, and dosing. Yet many hematology APPs and nurses, who are central to patient counseling, shared decision-making, and long-term adherence support (particularly in rural and resource-limited settings), remain unfamiliar with these agents. This Top 10 activity delivers concise, practical answers to the most common clinical questions about FVIIIα mimetic therapy to help hematology APPs and nurses individualize treatment and improve outcomes for people living with hemophilia A.

Educational Objectives

After completing this activity, the participant should be better able to:

• Summarize the mechanisms of action of novel and emerging FVIIIα mimetic therapies for hemophilia A
• Evaluate clinical efficacy, safety, and dosing considerations associated with FVIIIα mimetic therapies for hemophilia A
• Apply knowledge of FVIIIα mimetic therapies to support individualized treatment planning and shared decision-making for people with hemophilia A

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Global Education Group and Integritas Communications. Global Education Group is jointly accredted by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Associates Credit Designation

Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associates Continuing Education 

Global Education Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit(s). Approval is valid until October 30, 2027. PAs should only claim credit commensurate with the extent of their participation.

Global Contact Information

For information about the joint accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, review the activity content in its entirety, and complete the postactivity test and evaluation. A score of 70% or higher on the posttest is required to receive a certificate of credit.

Fee & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.

The faculty have the following relevant financial relationships with ineligible companies:

Maya Bloomberg, MSN, APRN

• Consultant: Genentech, Novo Nordisk, Pfizer, Sanofi, Takeda

The planners and managers at Global and Integritas have no relevant financial relationships with ineligible companies to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.